| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 14,7 M € | +4.3% | 14,1 M € | +16.0% | 12,2 M € | +1.5% | 12,0 M € | -21.5% | 15,3 M € | — | — | — | — | — | ||||||
| Gross margin | — | — | — | — | — | 1,6 M € | +64.5% | 991,6 k € | +1102.4% | -98,9 k € | -346.5% | -22,2 k € | +92.1% | -280,7 k € | ||||||
| EBITDA | 783,1 k € | +257.5% | -497,2 k € | -594.3% | 100,6 k € | -71.4% | 351,9 k € | -80.0% | 1,8 M € | +67.1% | 1,1 M € | +111.5% | 496,9 k € | +217.1% | -424,3 k € | -123.0% | -190,3 k € | +43.5% | -336,8 k € | |
| Operating profit | 95,9 k € | +108.2% | -1,2 M € | -998.6% | -106,9 k € | -151.9% | 205,9 k € | -87.4% | 1,6 M € | +70.7% | 959,4 k € | +125.9% | 424,6 k € | +188.2% | -481,7 k € | -106.9% | -232,8 k € | +32.1% | -342,6 k € | |
| Profit/loss | -374,5 k € | +74.3% | -1,5 M € | -429.0% | -275,4 k € | -866.0% | 36,0 k € | -96.7% | 1,1 M € | +32.5% | 834,2 k € | +117.2% | 384,1 k € | +178.6% | -488,6 k € | -91.6% | -255,0 k € | +27.2% | -350,1 k € | |
| Equity | 248,0 k € | -60.2% | 622,5 k € | -65.1% | 1,8 M € | -13.4% | 2,1 M € | +1.8% | 2,0 M € | +120.0% | 920,4 k € | +967.7% | 86,2 k € | +128.9% | -297,9 k € | -428.5% | 90,7 k € | +190.6% | -100,1 k € | |
| Total assets | 12,5 M € | +8.1% | 11,6 M € | +54.1% | 7,5 M € | +41.1% | 5,3 M € | -9.1% | 5,9 M € | +90.5% | 3,1 M € | +56.1% | 2,0 M € | +46.2% | 1,4 M € | +62.5% | 830,6 k € | +130.9% | 359,7 k € | |
| Cash | 93,4 k € | -88.0% | 776,7 k € | +65.1% | 470,4 k € | +366.6% | 100,8 k € | -92.5% | 1,4 M € | +251.1% | 384,8 k € | +11059.9% | 3,4 k € | -58.6% | 8,3 k € | -89.0% | 75,5 k € | +237.8% | 22,4 k € | |
| Debts | 12,3 M € | +12.9% | 10,9 M € | +89.4% | 5,7 M € | +75.6% | 3,3 M € | -15.0% | 3,8 M € | +85.0% | 2,1 M € | +14.9% | 1,8 M € | +16.8% | 1,5 M € | +115.3% | 719,4 k € | +58.3% | 454,5 k € | |
| Staff | 55,2 | 50,6 | 16,6 | 14 | 12,5 | 9,8 | 8,3 | 6,5 | — | 1,5 | ||||||||||
Public limited company · Antwerpen · incorporated on 22/12/2015 · 55,2 ETP
Public limited company loss-making in the latest fiscal year. Cash position declining (-88.0%).
Solid counterparty for a standard engagement.
Magis-Pharma is a Public limited company incorporated in 2015. Its main activity is: Wholesale of pharmaceutical goods. Its registered office is in Antwerpen. It employs on average 55,2 ETP workers (FTE).
Key indicators
7-day free trial, no credit card required.
7-day free trial, no credit card required.
7-day free trial, no credit card required.
Source: Belgian Official Gazette